Press Releases – BeiGene SSE

Press Releases

Jan 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia    read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA    read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List    read more...
Jan 17, 2023
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium    read more...
Jan 04, 2023
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference    read more...
Dec 30, 2022
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab    read more...
Dec 13, 2022
 BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH    read more...
Dec 09, 2022
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors    read more...
Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022    read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)    read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care    read more...
Nov 10, 2022
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers    read more...
Nov 09, 2022
BeiGene Reports Third Quarter 2022 Financial Results    read more...
Nov 04, 2022
BeiGene to Present at Upcoming Investor Conferences    read more...
Nov 03, 2022
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting    read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma    read more...
Oct 26, 2022
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America    read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL    read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial    read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment    read more...